339 related articles for article (PubMed ID: 33949667)
1. Downregulation of ARID1B, a tumor suppressor in the WNT subgroup medulloblastoma, activates multiple oncogenic signaling pathways.
Deogharkar A; Singh SV; Bharambe HS; Paul R; Moiyadi A; Goel A; Shetty P; Sridhar E; Gupta T; Jalali R; Goel N; Gadewal N; Muthukumar S; Shirsat NV
Hum Mol Genet; 2021 Aug; 30(18):1721-1733. PubMed ID: 33949667
[TBL] [Abstract][Full Text] [Related]
2. Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups.
Ellison DW; Dalton J; Kocak M; Nicholson SL; Fraga C; Neale G; Kenney AM; Brat DJ; Perry A; Yong WH; Taylor RE; Bailey S; Clifford SC; Gilbertson RJ
Acta Neuropathol; 2011 Mar; 121(3):381-96. PubMed ID: 21267586
[TBL] [Abstract][Full Text] [Related]
3. Downregulation of CRX, a Group 3-specific oncogenic transcription factor, inhibits TGF-β/activin signaling in medulloblastoma cells.
Masurkar SA; Deogharkar A; Bharambe HS; Shirsat NV
Biochem Biophys Res Commun; 2021 Sep; 568():76-82. PubMed ID: 34192607
[TBL] [Abstract][Full Text] [Related]
4. RBM5 Acts as Tumor Suppressor in Medulloblastoma through Regulating Wnt/β-Catenin Signaling.
Yu J; Ji G; Shi W; Zhao R; Shen W; Zheng J; Li H; Jiang F
Eur Neurol; 2020; 83(3):242-250. PubMed ID: 32610314
[TBL] [Abstract][Full Text] [Related]
5. Downregulation of miR-204 expression defines a highly aggressive subset of Group 3/Group 4 medulloblastomas.
Bharambe HS; Paul R; Panwalkar P; Jalali R; Sridhar E; Gupta T; Moiyadi A; Shetty P; Kazi S; Deogharkar A; Masurkar S; Yogi K; Kunder R; Gadewal N; Goel A; Goel N; Chinnaswamy G; Ramaswamy V; Shirsat NV
Acta Neuropathol Commun; 2019 Apr; 7(1):52. PubMed ID: 30944042
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of WNT signaling attenuates self-renewal of SHH-subgroup medulloblastoma.
Rodriguez-Blanco J; Pednekar L; Penas C; Li B; Martin V; Long J; Lee E; Weiss WA; Rodriguez C; Mehrdad N; Nguyen DM; Ayad NG; Rai P; Capobianco AJ; Robbins DJ
Oncogene; 2017 Nov; 36(45):6306-6314. PubMed ID: 28714964
[TBL] [Abstract][Full Text] [Related]
7. Restoration of miR-193a expression is tumor-suppressive in MYC amplified Group 3 medulloblastoma.
Bharambe HS; Joshi A; Yogi K; Kazi S; Shirsat NV
Acta Neuropathol Commun; 2020 May; 8(1):70. PubMed ID: 32410663
[TBL] [Abstract][Full Text] [Related]
8. Histopathological and molecular prognostic markers in medulloblastoma: c-myc, N-myc, TrkC, and anaplasia.
Eberhart CG; Kratz J; Wang Y; Summers K; Stearns D; Cohen K; Dang CV; Burger PC
J Neuropathol Exp Neurol; 2004 May; 63(5):441-9. PubMed ID: 15198123
[TBL] [Abstract][Full Text] [Related]
9. MiR-592 activates the mTOR kinase, ERK1/ERK2 kinase signaling and imparts neuronal differentiation signature characteristic of Group 4 medulloblastoma.
Paul R; Bapat P; Deogharkar A; Kazi S; Singh SKV; Gupta T; Jalali R; Sridhar E; Moiyadi A; Shetty P; Shirsat NV
Hum Mol Genet; 2021 Nov; 30(24):2416-2428. PubMed ID: 34274968
[TBL] [Abstract][Full Text] [Related]
10. p53 Function Is Compromised by Inhibitor 2 of Phosphatase 2A in Sonic Hedgehog Medulloblastoma.
Wei Y; Maximov V; Morrissy SA; Taylor MD; Pallas DC; Kenney AM
Mol Cancer Res; 2019 Jan; 17(1):186-198. PubMed ID: 30224541
[TBL] [Abstract][Full Text] [Related]
11. Subgroup-specific prognostic signaling and metabolic pathways in pediatric medulloblastoma.
Park AK; Lee JY; Cheong H; Ramaswamy V; Park SH; Kool M; Phi JH; Choi SA; Cavalli F; Taylor MD; Kim SK
BMC Cancer; 2019 Jun; 19(1):571. PubMed ID: 31185958
[TBL] [Abstract][Full Text] [Related]
12. Deep sequencing of WNT-activated medulloblastomas reveals secondary SHH pathway activation.
Iorgulescu JB; Van Ziffle J; Stevers M; Grenert JP; Bastian BC; Chavez L; Stichel D; Buchhalter I; Samuel D; Nicolaides T; Banerjee A; Mueller S; Gupta N; Tihan T; Bollen AW; Northcott PA; Kool M; Pfister S; Korshunov A; Perry A; Solomon DA
Acta Neuropathol; 2018 Apr; 135(4):635-638. PubMed ID: 29435664
[No Abstract] [Full Text] [Related]
13. Dissecting the genomic complexity underlying medulloblastoma.
Jones DT; Jäger N; Kool M; Zichner T; Hutter B; Sultan M; Cho YJ; Pugh TJ; Hovestadt V; Stütz AM; Rausch T; Warnatz HJ; Ryzhova M; Bender S; Sturm D; Pleier S; Cin H; Pfaff E; Sieber L; Wittmann A; Remke M; Witt H; Hutter S; Tzaridis T; Weischenfeldt J; Raeder B; Avci M; Amstislavskiy V; Zapatka M; Weber UD; Wang Q; Lasitschka B; Bartholomae CC; Schmidt M; von Kalle C; Ast V; Lawerenz C; Eils J; Kabbe R; Benes V; van Sluis P; Koster J; Volckmann R; Shih D; Betts MJ; Russell RB; Coco S; Tonini GP; Schüller U; Hans V; Graf N; Kim YJ; Monoranu C; Roggendorf W; Unterberg A; Herold-Mende C; Milde T; Kulozik AE; von Deimling A; Witt O; Maass E; Rössler J; Ebinger M; Schuhmann MU; Frühwald MC; Hasselblatt M; Jabado N; Rutkowski S; von Bueren AO; Williamson D; Clifford SC; McCabe MG; Collins VP; Wolf S; Wiemann S; Lehrach H; Brors B; Scheurlen W; Felsberg J; Reifenberger G; Northcott PA; Taylor MD; Meyerson M; Pomeroy SL; Yaspo ML; Korbel JO; Korshunov A; Eils R; Pfister SM; Lichter P
Nature; 2012 Aug; 488(7409):100-5. PubMed ID: 22832583
[TBL] [Abstract][Full Text] [Related]
14. WNT activation by lithium abrogates TP53 mutation associated radiation resistance in medulloblastoma.
Zhukova N; Ramaswamy V; Remke M; Martin DC; Castelo-Branco P; Zhang CH; Fraser M; Tse K; Poon R; Shih DJ; Baskin B; Ray PN; Bouffet E; Dirks P; von Bueren AO; Pfaff E; Korshunov A; Jones DT; Northcott PA; Kool M; Pugh TJ; Pomeroy SL; Cho YJ; Pietsch T; Gessi M; Rutkowski S; Bognár L; Cho BK; Eberhart CG; Conter CF; Fouladi M; French PJ; Grajkowska WA; Gupta N; Hauser P; Jabado N; Vasiljevic A; Jung S; Kim SK; Klekner A; Kumabe T; Lach B; Leonard JR; Liau LM; Massimi L; Pollack IF; Ra YS; Rubin JB; Van Meir EG; Wang KC; Weiss WA; Zitterbart K; Bristow RG; Alman B; Hawkins CE; Malkin D; Clifford SC; Pfister SM; Taylor MD; Tabori U
Acta Neuropathol Commun; 2014 Dec; 2():174. PubMed ID: 25539912
[TBL] [Abstract][Full Text] [Related]
15. Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations.
Pugh TJ; Weeraratne SD; Archer TC; Pomeranz Krummel DA; Auclair D; Bochicchio J; Carneiro MO; Carter SL; Cibulskis K; Erlich RL; Greulich H; Lawrence MS; Lennon NJ; McKenna A; Meldrim J; Ramos AH; Ross MG; Russ C; Shefler E; Sivachenko A; Sogoloff B; Stojanov P; Tamayo P; Mesirov JP; Amani V; Teider N; Sengupta S; Francois JP; Northcott PA; Taylor MD; Yu F; Crabtree GR; Kautzman AG; Gabriel SB; Getz G; Jäger N; Jones DT; Lichter P; Pfister SM; Roberts TM; Meyerson M; Pomeroy SL; Cho YJ
Nature; 2012 Aug; 488(7409):106-10. PubMed ID: 22820256
[TBL] [Abstract][Full Text] [Related]
16. CTNNB1, AXIN1 and APC expression analysis of different medulloblastoma variants.
Silva Rd; Marie SK; Uno M; Matushita H; Wakamatsu A; Rosemberg S; Oba-Shinjo SM
Clinics (Sao Paulo); 2013; 68(2):167-72. PubMed ID: 23525311
[TBL] [Abstract][Full Text] [Related]
17. Medulloblastoma in China: clinicopathologic analyses of SHH, WNT, and non-SHH/WNT molecular subgroups reveal different therapeutic responses to adjuvant chemotherapy.
Zhang ZY; Xu J; Ren Y; Li KK; Ng HK; Mao Y; Zhong P; Yao Y; Zhou LF
PLoS One; 2014; 9(6):e99490. PubMed ID: 24932704
[TBL] [Abstract][Full Text] [Related]
18. Overexpressed TP73 induces apoptosis in medulloblastoma.
Castellino RC; De Bortoli M; Lin LL; Skapura DG; Rajan JA; Adesina AM; Perlaky L; Irwin MS; Kim JY
BMC Cancer; 2007 Jul; 7():127. PubMed ID: 17626635
[TBL] [Abstract][Full Text] [Related]
19. Molecular subgroups of adult medulloblastoma: a long-term single-institution study.
Zhao F; Ohgaki H; Xu L; Giangaspero F; Li C; Li P; Yang Z; Wang B; Wang X; Wang Z; Ai L; Zhang J; Luo L; Liu P
Neuro Oncol; 2016 Jul; 18(7):982-90. PubMed ID: 27106407
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological characteristics, molecular subgrouping, and expression of miR-379/miR-656 cluster (C14MC) in adult medulloblastomas.
Kaur K; Kakkar A; Kumar A; Purkait S; Mallick S; Suri V; Sharma MC; Julka PK; Gupta D; Suri A; Sarkar C
J Neurooncol; 2016 Dec; 130(3):423-430. PubMed ID: 27576698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
